<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-040374</identifier>
<setSpec>0211-6995</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Improved short-term cardiovascular profile after simultaneous pancreas-kidney transplantation</dc:title>
<dc:description xml:lang="en">The prognosis of type 1 diabetes mellitus (T1DM) patients with chronic renalfailure (CRF) improves after simultaneous pancreas-kidney (SPK) transplantation.In order to evaluate the changes in cardio-vascular risk (CVR) factors after SKP,we studied nine recipients before and 6 months after SPK. There were five femalesand four males, with a mean age of 37 ± 8 years, duration of diabetes of 24± 5 years, three of them before starting dialysis, and six on dialysis (hemodialysis= 5; peritoneal dialysis = 1). Before SPK, all patients received anti-hypertensivetherapy (1-4 drugs; mean 2.2 ± 0.9) and eight received statins. At 6 months afterSPK, all patients were under triple immunosuppressive therapy (steroids + tacrolimus+ MMF) without statins. They had normal renal function (Plasma Creatinine=1.2 ± 0.3 mg/dl) and pancreatic endocrine function (glycemia = 80 ± 8 mg/dl).HbA1c decreased significantly (8.4 ± 1.2 vs 4.7 ± 0.6%; p  7% in seven patients before SPK and in none 6 months after SKP transplantation(p &lt; 0.001). Although Body Mass Index increased (23 ± 2 vs 25 ± 3 kg/m2;p &lt; 0.05), plasma triglycerides decreased (130 ± 51 vs 88 ± 33 mg/dl; p &lt; 0.05),and total cholesterol, LDL-cholesterol and HDL-cholesterol were similar. Systolicand diastolic blood pressure (BP) decreased (156 ± 7 vs 133 ± 15; p &lt; 0.01 and96 ± 7 vs 79 ± 9; p &lt; 0.007) with only two patients on anti-hypertensive therapy(1 drug). Likewise, before transplantation all patients were hypertensive (six grade1 and three grade 2) while this was observed in only two at the end of followup(both grade 1) (p &lt; 0.001). In conclusion, SPK transplantation with good renaland pancreatic function is associated with a short-term improvement in CVR profile</dc:description>
<dc:creator>Morcillo, L</dc:creator>
<dc:creator>González-Posada, J. M</dc:creator>
<dc:creator>Hernández, D</dc:creator>
<dc:creator>Pérez Tamajón, L</dc:creator>
<dc:creator>Marrero, D</dc:creator>
<dc:creator>Laynez, I</dc:creator>
<dc:creator>Bravo, A</dc:creator>
<dc:creator>Meneses, M</dc:creator>
<dc:creator>Rodríguez, C</dc:creator>
<dc:creator>Caballero, A</dc:creator>
<dc:creator>Alarco, A</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El pronóstico del paciente con diabetes mellitus tipo 1 (DMT1) e insuficienciarenal crónica (IRC) mejora tras el trasplante reno-pancreático (TRP). Con el fin deevaluar los cambios en los factores de riesgo cardio-vascular (RCV) se analizaronnueve pacientes que recibieron un TRP, antes (pre-TRP) y a los 6 meses de seguimiento(pos-TRP). Tres pacientes no habían iniciado diálisis, cinco estaban enhemodiálisis, y uno en diálisis peritoneal. Pre-TRP todos los pacientes recibían hipotensores(nº de fármacos = 2,2 ± 0,9; rango 1-4) y ocho de ellos estatinas. Eltratamiento inmunosupresor consistió en Tacrolimus, Micofenolato Mofetil y esteroides.Pos-TRP todos mantenían función renal y pancreática normales (creatininaplasmática 1,2 ± 0,3 mg/dl; glucemia = 80 ± 8 mg/dl) sin necesidad de estatinas.La HbA1c descendió de forma significativa (8,4 ± 1,2 vs 4,7 ± 0,6%; p &lt;0,007), presentando un valor superior al 7%, siete pacientes pre-TRP frente a ningunopos-TRP (p &lt; 0,001). Aunque el Índice de Masa Corporal aumentó (23 ± 2vs 25 ± 3 kg/m2; p &lt; 0,05), los triglicéridos descendieron (130 ± 51 vs 88 ± 33mg/dl; p &lt; 0,05), y el colesterol total, HDL-colesterol, LDL-colesterol fueron similares.La tensión arterial sistólica (TAs) y diastólica (TAd) descendió de forma significativa(156 ± 7 vs 133 ± 15; p &lt; 0,01 y 96 ± 7 vs 79 ± 9; p &lt; 0,007 respectivamente)y sólo dos pacientes recibían hipotensores pos-TRP (1 fármaco). Enconclusión, estos datos sugieren que a corto plazo el TRP mejora algunos de losfactores de RCV lo que pudiera traducirse en una optimización del pronóstico amás largo plazo</dc:description>
<dc:source>Nefrologia;25(3): 315-321, mayo 2005. tab, graf</dc:source>
<dc:identifier>ibc-040374</dc:identifier>
<dc:title xml:lang="es">Evolución a corto plazo de los factores de riesgo cardiovascular tras el trasplante reno-pancreático</dc:title>
<dc:subject>^d29622</dc:subject>
<dc:subject>^d29545</dc:subject>
<dc:subject>^d1812^s22002</dc:subject>
<dc:subject>^d29504</dc:subject>
<dc:subject>^d22190^s22002</dc:subject>
<dc:subject>^d3944^s22062</dc:subject>
<dc:subject>^d33014^s22073</dc:subject>
<dc:subject>^d7852</dc:subject>
<dc:subject>^d29407</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d29475</dc:subject>
<dc:subject>^d2360^s22032</dc:subject>
<dc:subject>^d331</dc:subject>
<dc:subject>^d3951^s22009</dc:subject>
<dc:subject>^d3944^s22009</dc:subject>
<dc:subject>^d3951^s22067</dc:subject>
<dc:subject>^d3951^s22032</dc:subject>
<dc:subject>^d962^s22073</dc:subject>
<dc:subject>^d3944^s22012</dc:subject>
<dc:subject>^d50497</dc:subject>
<dc:subject>^d7152</dc:subject>
<dc:subject>^d7130</dc:subject>
<dc:type>article</dc:type>
<dc:date>200505</dc:date>
</metadata>
</record>
</ibecs-document>
